This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bruce, W. R. Search for Related Content PubMed PubMed Citation Articles by Bruce, W. R. Related Collections Commentary Key Article

Counterpoint: From Animal Models to Prevention of Colon Cancer. Criteria for Proceeding from Preclinical Studies and Choice of Models for Prevention Studies¹

Department of Nutritional Sciences, University of Toronto, Toronto, Ontario M5S 3E2, Canada

Corpet and Pierre (D. E. Corpet and F. Pierre, Cancer Epidemiol. Biomark. Prev., 12: 391-400, 2003) have reviewed the prevention studies made with the azoxymethane rat and Min mouse colon cancer models, and have shown that many agents reduce the numbers of these experimental tumors. They suggest that agents with preventive activity with little or no toxicity should be evaluated in clinical intervention studies without delay. I think that the decision to proceed to a clinical trial is more complex, and involves an understanding of the safety of the agent and of the strength and consistency of the preclinical data. However, I am also impressed by the wide range of agents that have been found to affect the development of colon cancer in animals. This suggests that human colon cancer may be the consequence of many different dietary and lifestyle deficiencies, a view supported by the observation that normal mice develop colon cancer when fed diets deficient in several food components known to prevent tumors with the azoxymethane rat model [Newmark, H. L. et al., Carcinogenesis (Lond.), 22: 1871–1875, 2001]. There is a clear need to evaluate the preventive effects of additional combinations of these agents, identified perhaps from the Corpet and Pierre review (D. E. Corpet and F. Pierre, Cancer Epidemiol. Biomark. Prev., 12: 391-400, 2003), or from actual human high-risk diets. With diets that increase the risk of "spontaneous cancer" in hand, the stage would be set for assessing the most effective ways to reduce colon cancer risk, again first with animal studies, then clinical trials, and then perhaps population studies.

Commentary

Point: From Animal Models to Prevention of Colon Cancer. Systematic Review of Chemoprevention in Min Mice and Choice of the Model System

Denis E. Corpet and Fabrice Pierre
Cancer Epidemiol. Biomarkers Prev. 2003 12: 391-400. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				G. Bobe, L. B. Sansbury, P. S. Albert, A. J. Cross, L. Kahle, J. Ashby, M. L. Slattery, B. Caan, E. Paskett, F. Iber, et al. Dietary Flavonoids and Colorectal Adenoma Recurrence in the Polyp Prevention Trial Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1344 - 1353. [Abstract] [Full Text] [PDF]

				P. Lance and S. R. Hamilton Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention Cancer Prevention Research, June 1, 2008; 1(1): 4 - 8. [Full Text] [PDF]

				A. Y. Issa, S. R. Volate, S. J. Muga, D. Nitcheva, T. Smith, and M. J. Wargovich Green tea selectively targets initial stages of intestinal carcinogenesis in the AOM-ApcMin mouse model Carcinogenesis, September 1, 2007; 28(9): 1978 - 1984. [Abstract] [Full Text] [PDF]

				M. Singh and L. Johnson Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin. Cancer Res., September 15, 2006; 12(18): 5312 - 5328. [Abstract] [Full Text] [PDF]

				A. J. Gescher and W. P. Steward Relationship between Mechanisms, Bioavailibility, and Preclinical Chemopreventive Efficacy of Resveratrol: A Conundrum Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 953 - 957. [Full Text] [PDF]